the C-3 amide moiety have been prepared. In vitro antibacterial activity of these new analogs against Gram-positive organisms, particularly methicillin-resistant strains of Staphylococci species has been described.
Coumermycin Ax (1) is a coumarin-containing antibiotic, discovered nearly two decades ago.1"Ĉ oumermycin Ax and structurally related antibiotics4) such as novobiocin (2) are currently undergoing a renewed interest for two major reasons. One is that this class of antibiotics, particularly 1, possesses potent antibacterial activity against methicillin-resistant strains of Staphylococci species5~7) which have become clinically important pathogens in recent years.r>8) The other reason is their mechanism of action. Unlike other antibiotics such as /3-lactams and macrolides, this class of antibiotics is known to act as an inhibitor of bacterial DNAgyrase.9'10) Although extensive studies on semi-synthetic coumermycin analogs werereported in the past,n) because of the resurgent interest, wedecided to reinvestigate the chemical modification of 1. Our goal was to search for new analogs having improved pharmaceutical properties, such as good water-solubility and oral absorbability, while retaining the good antibacterial activity particularly against methicillin-resistant strains of Staphylococci species.
In spite of its excellent antibacterial activity, 1 is poorly soluble in water which makes parenteral administration unsatisfactory. This poor water-solubility is also believed to be partly responsible for its unfavorable pharmacokinetics and irritation liability.10 Wereasoned that this poor water-solubility was primarily due to its large molecular size, the presence of two coumarin moieties and the lack of strong polar substituents in the molecule. Previous workers have reported10 a number of semisynthetic analogs which are monomericnoviosyloxycoumarin derivatives having a variety of carboxyamido substituents at the 3-position of the coumarin ring such as benzamido derivative 312) and 4-hydroxy-3-(3-methylbutyl)benzamido derivative 4.13) However, most of them did not carry a strong polar substituent such as an amino group or a carboxylic acid moiety. Therefore, we have specifically directed our efforts towards the introduction of such a strong polar substituent at the C-3 amide moiety. This paper describes the preparation of new semi-synthetic analogs which contain aminoacetamide moieties 5 and 6, and aminoethoxybenzamide group 7. The latter compound 7 was chosen because the 4-hydroxy-3-(3-methylbutyl)benzamide derivative 4 was reported to be one of the most potent analogs.10 Wealso describe here the preparation of a carboxy analog 8a and its carbamoyl derivative 8b. In vitro antibacterial activity of these newanalogs and their synthetic intermediates are also glycine hydrochlorides and PC15, furnished directly, in one step, 6a and 6b in 69 and 25% yield, respectively.
The aminoethoxybenzamido analog 7 was prepared using 9 as a starting intermediate. Treatment of ethyl 3-prenyl-4-hydroxybenzoate17) (22) with 2-bromoethanol under the Mitsunobu conditions1*0 gave bromoethoxybenzoate 23 which was converted to the azide 24. Hydrolysis of 24 to carboxylic acid 25 followed by treatment with oxalyl chloride provided 3-prenyl-4-(2-azidoethoxy)benzoyl chloride (26) in ca. 50% overall yield from 22. Condensation of 9 with 26 in pyridine afforded, in 33% yield, 27 which was converted with NH4OH-MeOH to 2/-hydroxy compound 28 in 22%
yield.
The azido and prenyl moieties of 28 were both hydrogenated with Pd-C in EtOH containing dil HC1, giving 7 in 66% yield as the hydrochl oride.
Carboxypyrrole derivative 29a was prepared in 16% yield as a minor by-product during a larger scale synthesis of 2/-acetyl oxazolocoumarin ll which involved heating 1 with Ac2O and pyridine.14) Regiochemistry of the carboxy group on the pyrrole was established as /3-carboxypyrrole, shown in 29a, based on the work of Kawaguchi and co-workers.2) This clearly indicates that the^-carboxyarnide of the central pyrrole in 1 was more readily cleaved than the a-carboxyamide moiety under these conditions. This agrees with the long knownfact that under acidic conditions /3-carboxypyrrole esters are selectively cleaved in the presence of a-carboxy esters to pyrrole-/3-carboxylic acids.19) The 2'-acetyl group in 29a was removed with NH4OH-MeOHto furnish 8a in 22% yield. The /3-carbamoylpyrrole derivative 8b was prepared in 10% yield from 29a. Treatment of 29a with 7V,7V'-carbonyldiimidazole followed by liq NH3 afforded 29b which was converted to 8b by the removal of the 2'-acetyl group with NH4OH-MeOH. The low yield is partly due to the formation of a substantial amount of a polar by-product in the carbamoylation process.
In Vitro Antibacterial Activity
In vitro antibacterial activity of new semi-synthetic coumermycin analogs, 5a, 5b, 6a, 6b, 17a, 17b, 20a, 7, 8a and 8b, is summarized in the Table 1 . Coumermycin A1 (1), benzamido analog 3 and 4-hydroxy-3-(3-methylbutyl)benzamido analog 4 are included for comparison. The benzamido analog 3 was used traditionally as a standard for comparison and the 4-hydroxybenzamido derivative 4 was reported to be one of the most active compounds amongthe semi-synthetic coumermycinanalogs.n) Selected Gram-positive organisms listed in this table are Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, which includes methicillin-resistant strains, and a methicillin-resistant strain of Staphylococcus epidermidis. Methicillin-resistant strains of S. aureus A20700 and A25070 were chosen as representatives of strains which are sensitive to 1 and less sensitive to 1, respectively.
The alanine and phenylglycine analogs, 5 and 6, showed only modest antibacterial activity. The phenylglycine series 6 and 20a were generally more active than the alanine series 5 and 17. Interestingly, JV-CBZderivatives of (£)-alanine and O$)-phenylglycine analogs, 17a and 20a, showed much better anti-Staphylococcal activity than the parent amino acid analogs, 5a and 6a, and they possessed comparable antibacterial activity to the benzamido analog 3. The aminoethoxybenzamido derivative 7 appeared to be much more soluble than 1 or the corresponding hydroxybenzamido analog 4. Although 7 was generally less potent than 4, 7 exhibited good antibacterial activity against Staphylococci SEPT. 1989 species including the methicillin-resistant strain A25070 which was resistant to most of the semi-synthetic analogs.
The carboxy-and carbamoyl-containing analogs, 8a and 8b were found to possess only modest antibacterial activity. Amongnew semi-synthetic analogs described here, 7 was found to be the most promising because of its improved solubility and uniformly good antibacterial activity, particularly against methicillin-resistant strains of Staphylococci species.
Exp erim ental MP's were determined on a MEL-TEMP apparatus and are uncorrected. Optical rotations were measured with a Perkin-Elmer Model 241 polarimeter. IR spectra were recorded on a PerkinElmer Model 1800 fourier transformation (FT)-IR spectrophotometer. The UVspectra were obtained with a Hewlett-Packard 8452A Diode Array spectrophotometer. The XHNMRspectra were taken with either a Bruker WM360(360 MHz), a Bruker AM300 (300 MHz), or a Varian VXR-200 (200 MHz)NMRspectrometer. TMSor residual protonated solvent was used as an internal reference. Splitting patterns: s, singlet; d, doublet, t, triplet; dd, doublet of doublets; m, multiplet; br, broad. MSwere obtained on either a Kratos MS25RFA(fast atom bombardment; FAB) using xenon atom bombardment or a Finnigan 4500 electron impact-chemical ionization (EI-CI) mass spectrometer. 3-Nitrobenzyl alcohol or thioglycerol was used as the supporting matrix in FAB-MS measurement. High resolution mass spectra (HR-MS)were recorded on a Kratos MS-50instrument. THFwas freshly distilled from sodium benzophenone ketyl. Freshly opened anhydrous diethyl ether (Aldrich) was used without further treatment. Pyridine was distilled from CaH2and stored over NaOH.Anhydrous solvents were obtained, drying over molecular sieves 4A (CH2C12)or 3A (DMF).
iV-CBZ-L-Phenylglycine20) (14a) and ethyl 4-hydroxy-3-prenylbenzoate17) (22) were prepared according to the reported procedures. The 2'-acetyl PNC-amine 9 and PNC-amine 10 were prepared as described in ref 14 and not purified. Analytical and preparative TLC was performed by using precoated plates (Silica gel 60A, MKGF,Whatman and Silica gel 60 F254, E. Merck, respectively). To a stirred solution of iV-CBZ-L-alanine (13a) (323 mg, L45 mmol) in anhydrous THF (10 ml) was injected JV-methylmorpholine (160 //I, 1.45 mmol) and then isobutyl chloroformate (188 /4, 1.45 mmol) at -15--10°C (ice-MeOH bath) under a nitrogen atmosphere. A few minutes after, to this mixture was added iV-methylmorpholine (160 //I, 1.45 mmol) and then a solution of 2/-acetyl PNCamine hydrochloride 9 (825 mg, 1.45 mmol) in anhydrous THF (10 ml) in 5 minutes. The mixture was stirred at ambient temperature for 3.5 hours. This was diluted with EtOAc, washed successively with dil NaHCO3, dil HC1 and then brine, dried over Na2SO4 and concentrated in vacuo to yield 1.124 g of a crude product. This was purified by column chromatography (SiO2; EtOAc -CH2C12, 1 :4 to 1 : 1), trituration with Et2O and then recrystallization from EtOH -CH2C12 to give 537 mg (0.73 mmol, yield 50.3%) of 16a as off-white crystals: MP 150-152°C; UV^a°xH nm (e) 236 (17, 200) 
(17a) To a suspension of 16a (368 mg, 0.5 mmol) in MeOH(4ml) was added cone NH4OH-MeOH (1 :9) (16 ml) to dissolve. This solution was stirred at room temperature for 3 days. Evaporation of the solvent to dryness gave white glassy solid which was purified by column chromatography (SiO2 ; MeOH-CH2Cl2, 1 :24) and precipitation from CH2C12 -hexane to give 154 mg (0.22 mmol, yield 44%) of 17a as white powder: MP 130°C (dec); UV ;g£g? nm (s) 236 (17, A solution of 17a (45 mg, 0.065 mmol) in abs EtOH (15 ml) was mixed with 1 n HC1 (0.13 ml, 0.13 mmol) and 10% Pd-C (20mg). This mixture was hydrogenated in a Parr apparatus at H2, 2.5 kg/cm2, room temperature for 1.5 hours, by which time TLC (MeOH -CH2C12, 1 : 9) indicated the reaction was complete. The catalyst was filtered over Celite and the filtrate was evaporated to yield yellowish powder which was purified by column chromatography (SiO2; cone NH4OH-MeOH -CH2C12, 3 :27 : 70) to obtain 31 mg (0.055 mmol, yield 85%) of5a as white powder. This was dissolved in a minimum amount of 2-PrOH, removing any insoluble materials. Compounds 16b, 17b, 5b, 19a and 20a
The title compounds were prepared from 9 using iV-CBZ-D-alanine (13b) or iV-CBZ-L-phenylglycine20) (14a) as described above for the preparation of 16a, 17a and 5a. To a stirred suspension of PNC-amine hydrochloride 10 (468 mg, 0.892 mmol) in CH2C12 (40 ml) was added Ar,7V-dimethylaniline (260 /A, 2.03 mmol; dried over KOH) and then 15a (187 mg, 0.9 mmol) in portions at 0~5°C under a dry argon atmosphere. The mixture was stirred for 15 minutes and then anhydrous THF(13 ml) was added. The mixture was stirred at 0~5°C for 4.5 hours and an additional hour after removing the cooling bath. The solvents were evaporated and the crude residue was purified by column chromatography (SiO2; coned NH4OH-MeOH-CH2C12, The title compound was prepared from 15b by the method described for the S-isomer 6a: MP 15O~18O°C (dec); UV^^a°xH nm (e) 280 (26,300), 310 (16,300); IR (KBr) cm"1 1700, 1610; XH NMR (360 MHz, CD3OD) 8 1.16 (3H, s, 5'-CH3), 1.36 (3H, s, 5'-CH3), 2.30 (3H, s, 5"-CH3), 2.32 (3H, s,  8-CH3), 3.52 (3H, s, 4/-OCH3), 3.71 (1H, d, /=10Hz, 4' -H 4-(2-Azidoethoxy)-3 -(3 -methyl-2-butenyl)benzoic Acid (25) A suspension of 24 (1.21 g, 4.00mmol) in MeOH(45ml) was mixed with 1 n NaOH (15ml) and the mixture was heated at reflux for 7.5 hours. The MeOHwas evaporated in vacuo and the residue was dissolved in H2O, removing any insoluble materials. This clear filtrate was acidified with 6 n HC1 (ca. 3 ml) in an ice-bath. The precipitate was filtered and dried in vacuo to give 950 mg (3. 
onyl)novio syl oxy]coumarin (27) To a stirred solution of 9 (820 mg, 1.45 mmol) in pyridine (20 ml) was added the acid chloride 26 (470 mg, 1.60 mmol) dropwise through a syringe at -30°C under an atmosphere of argon. The cooling bath was removed and the mixture was stirred at ambient temperature for 20 hours. This was diluted with CH2C12, washed successively with cold 3 n HC1, satd NaHCO3and brine. The organic phase was dried (Na2SO4) and concentrated in vacuo. To a solution of 1 (55.5 g, 50 mmol) in pyridine (300 ml) was added acetic anhydride (100ml) and the mixture heated at reflux for 3 hours. After cooling, this mixture was poured slowly onto a stirred mixture of 3 n HC1 (2 liters) and ice cubes (2 liters). The brown precipitate formed was filtered, washed with H2Oand dried in vacuo. This solid was dissolved in warm CH2C12(500 ml) and placed on a pad consisting of a thin-layer of Celite (ca. 50 g) over silica gel (500 g). After eluting with EtOAc-CH2Cl2 (1 :4) to obtain oxazole ll (26g), the pad was eluted with MeOH-EtOAc(1 :1, 2 liters). All MeOH -EtOHeluents were combined, and concentrated in vacuo to a volume of approximately 500 ml. Insoluble materials were removed by filtration through a Celite pad and the filtrate was concentrated to a volume of ca. 300 ml. This was left to stand at room temperature for 48 hours. The crystalline precipitate was collected, washed with EtOAc (3 x 100 ml) and dried to give 5.50 g (8.1 mmol, yield 16%) of the title compound 29a as off-white powder. An analytical sample was obtained by repeating the precipitation process described above: MP260°C (dec) ; Rf 0.65 (CH2Cl2 - A solution of 2/-acetate 29a (1.50 g, 2.20 mmol) in MeOH (20 ml) and cone NH4OH(3 ml) was stirred at room temperature for 24 hours by which time TLCindicated the reaction was complete. This was concentrated to a volume of ca. 10 ml and then poured onto a cold stirred 2 n HC1 solution (200 ml). The resulting precipitate was filtered, washed with H2O and dried to give 1.20 g of solid. This solid was dissolved in MeOH(50 ml) and EtOAc (50 ml) with heating and treated with activated carbon (1 g). The carbon was filtered while it was hot, washed with MeOH-EtOAc (1 : 1) and the filtrate and washings concentrated to a volume of ca. 35 ml. The insolubles were filtered and the filtrate concentrated to a volume of ca. 20 ml. The resulting precipitate was filtered, washed with EtOAc and dried to give 315 mg (0.492 mmol, yield 22.4%) of 8a as off-white powder: MP200~240°C (dec); Rf 0.45 (CH2C12 -MeOH -AcOH, 94:4:2); UV jlgg1 nm (e) 276 (27, 200) 
